Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future

Karen Allison; Deepkumar Patel; Omobolanle Alabi

doi:10.7759/cureus.11686

journal article Nov 24, 2020

Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future

Karen Allison Deepkumar Patel Omobolanle Alabi

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.11686

Topics

No keywords indexed for this article. Browse by subject →

References

26

[1]

Harasymowycz P, Birt C, Gooi P, et al.. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. J Ophthalmol. 2016, 2016:6509809. 10.1155/2016/6509809 10.1155/2016/6509809

[2]

Weinreb RN, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016, 2:16067. 10.1038/nrdp.2016.67 10.1038/nrdp.2016.67

[3]

Thomas S, Hodge W, Malvankar-Mehta M. The cost-effectiveness analysis of teleglaucoma screening device. PLoS One. 2015, 10:e0137913. 10.1371/journal.pone.0137913 10.1371/journal.pone.0137913

[4]

Imrie C, Tatham AJ. Glaucoma: the patient's perspective. Br J Gen Pract. 2016, 66:e371-373. 10.3399/bjgp16X685165 10.3399/bjgp16x685165

[5]

Hashemi H, Mohammadi M, Zandvakil N, Khabazkhoob M, Emamian MH, Shariati M, Fotouhi A. Prevalence and risk factors of glaucoma in an adult population from Shahroud, Iran. J Curr Ophthalmol. 2018, 31:366-372. 10.1016/j.joco.2018.05.003 10.1016/j.joco.2018.05.003

[6]

McMonnies CW. Glaucoma history and risk factors. J Optom. 2017, 10:71-78. 10.1016/j.optom.2016.02.003 10.1016/j.optom.2016.02.003

[7]

Wiggs JL, Pasquale LR. Genetics of glaucoma. Hum Mol Genet. 2017, 26:R21-R27. 10.1093/hmg/ddx184 10.1093/hmg/ddx184

[8]

Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016, 100:86-93. 10.1136/bjophthalmol-2015-307223 10.1136/bjophthalmol-2015-307223

[9]

Kreft D, Doblhammer G, Guthoff RF, Frech S. Prevalence, incidence, and risk factors of primary open-angle glaucoma - a cohort study based on longitudinal data from a German public health insurance. BMC Public Health. 2019, 19:851. 10.1186/s12889-019-6935-6 10.1186/s12889-019-6935-6

[10]

Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040

Yih-Chung Tham, Xiang Li, Tien Y. Wong et al.

Ophthalmology 2014 10.1016/j.ophtha.2014.05.013

[11]

Kyari F, Entekume G, Rabiu M, et al.. A Population-based survey of the prevalence and types of glaucoma in Nigeria: results from the Nigeria National Blindness and Visual Impairment Survey. BMC Ophthalmol. 2015, 15:176. 10.1186/s12886-015-0160-6 10.1186/s12886-015-0160-6

[12]

Kelly E, Wen Q, Haddad D, O'Banion J. Effects of an aging population and racial demographics on eye disease prevalence: projections for Georgia through 2050. Am J Ophthalmol. 2020, 210:35-40. 10.1016/j.ajo.2019.10.028 10.1016/j.ajo.2019.10.028

[13]

Centers for Disease Control and Prevention. Vision and Eye Health Surveillance System (VEHSS0). (2018). Accessed: November 23, 2020: https://www.cdc.gov/visionhealth/vehss/data/studies/glaucoma.html.

[14]

Fea AM, Hengerer F, Lavia C, Au L. Glaucoma quality of life. J Ophthalmol. 2017, 2017:4257151. 10.1155/2017/4257151 10.1155/2017/4257151

[15]

Quaranta L, Riva I, Gerardi C, Oddone F, Floriani I, Konstas AG. Quality of life in glaucoma: a review of the literature. Adv Ther. 2016, 33:959-981. 10.1007/s12325-016-0333-6 10.1007/s12325-016-0333-6

[16]

Prager AJ, Liebmann JM, Cioffi GA, Blumberg DM. Self-reported function, health resource use, and total health care costs among Medicare beneficiaries with glaucoma. JAMA Ophthalmol. 2016, 134:357-365. 10.1001/jamaophthalmol.2015.5479 10.1001/jamaophthalmol.2015.5479

[17]

Merepa SS, Kumah DB, Akowuah K, et al.. Socioeconomic influence of glaucoma on patients. EC Ophthalmology. 2018, 9:3-9.

[18]

Lawler T, Liu Y, Christensen K, Vajaranant TS, Mares J. Dietary antioxidants, macular pigment, and glaucomatous neurodegeneration: a review of the evidence. Nutrients. 2019, 11:1002. 10.3390/nu11051002 10.3390/nu11051002

[19]

Feldman RM, Cioffi GA, Liebmann JM, Weinreb RN. Current knowledge and attitudes concerning cost-effectiveness in glaucoma pharmacotherapy: a glaucoma specialists focus group study. Clin Ophthalmol. 2020, 14:729-739. 10.2147/OPTH.S236030 10.2147/opth.s236030

[20]

McGinley P, Ansari E, Sandhu H, Dixon T. The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK. J Med Econ. 2020, 23:106-112. 10.1080/13696998.2019.1646262 10.1080/13696998.2019.1646262

[21]

Schlenker MB, Trope GE, Buys YM. Comparison of United States and Canadian glaucoma medication costs and price change from 2006 to 2013. J Ophthalmol. 2015, 2015:547960. 10.1155/2015/547960 10.1155/2015/547960

[22]

Wang W, He M, Li Z, Huang W. Epidemiological variations and trends in health burden of glaucoma worldwide. Acta Ophthalmol. 2019, 97:e349-e355. 10.1111/aos.14044 10.1111/aos.14044

[23]

Hwang DK, Liu CJ, Pu CY, Chou YJ, Chou P. Persistence of topical glaucoma medication: a nationwide population-based cohort study in Taiwan. JAMA Ophthalmol. 2014, 132:1446-1452. 10.1001/jamaophthalmol.2014.3333 10.1001/jamaophthalmol.2014.3333

[24]

Thomas SM, Jeyaraman MM, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS. The effectiveness of teleglaucoma versus in-patient examination for glaucoma screening: a systematic review and meta-analysis. PloS One. 2014, 9:e113779. 10.1371/journal.pone.0113779 10.1371/journal.pone.0113779

[25]

Verma S, Arora S, Kassam F, Edwards MC, Damji KF. Northern Alberta remote teleglaucoma program: clinical outcomes and patient disposition. Can J Ophthalmol. 2014, 49:135-140. 10.1016/j.jcjo.2013.11.005 10.1016/j.jcjo.2013.11.005

[26]

Restrepo NA, Cooke Bailey JN. Primary open-angle glaucoma genetics in African Americans. Curr Genet Med Rep. 2017, 5:167-174. 10.1007/s40142-017-0131-8 10.1007/s40142-017-0131-8

Cited By

256

Lipidomic analysis reveals drug-induced lipoxin synthesis in glaucoma treatment

David J. Mathew, Shubham Maurya · 2026

JCI Insight

Medical glaucoma management: what’s new on the horizon?

Moon J. Lee, Ali Salimi · 2025

Expert Opinion on Emerging Drugs

DRAINAGE SURGERY IN GLAUCOMA TREATMENT: PAST, PRESENT AND FUTURE (LITERATURE REVIEW)

E.M. Gasimov, B.R. Babayeva · 2025

Azerbaijan Journal of Ophthalmology

Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma in Populations of African Descent

Jennifer M. Chang-Wolf, Tyler G. Kinzy · 2025

JAMA Ophthalmology

Illuminating eye care: the promise and future of red light therapy in ophthalmology

Fei Xue, Yating Zhou · 2025

Graefe's Archive for Clinical and E...

Metrics

256

Citations

26

References

Details

Published: Nov 24, 2020

Authors

Cite This Article

Karen Allison, Deepkumar Patel, Omobolanle Alabi (2020). Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. https://doi.org/10.7759/cureus.11686

Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future

You May Also Like